Charles River Laboratories International, Inc.
CRL · NYSE
12/28/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $4,050 | $4,129 | $3,976 | $3,540 |
| % Growth | -1.9% | 3.9% | 12.3% | – |
| Cost of Goods Sold | $2,718 | $2,627 | $2,513 | $2,206 |
| Gross Profit | $1,332 | $1,503 | $1,463 | $1,335 |
| % Margin | 32.9% | 36.4% | 36.8% | 37.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $751 | $748 | $665 | $620 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $353 | $137 | $147 | $125 |
| Operating Expenses | $1,104 | $885 | $812 | $745 |
| Operating Income | $227 | $617 | $651 | $590 |
| % Margin | 5.6% | 14.9% | 16.4% | 16.7% |
| Other Income/Exp. Net | -$134 | -$36 | -$28 | -$109 |
| Pre-Tax Income | $93 | $581 | $623 | $481 |
| Tax Expense | $68 | $101 | $130 | $82 |
| Net Income | $10 | $475 | $486 | $391 |
| % Margin | 0.3% | 11.5% | 12.2% | 11% |
| EPS | 0.2 | 9.27 | 9.57 | 7.77 |
| % Growth | -97.8% | -3.1% | 23.2% | – |
| EPS Diluted | 0.2 | 9.22 | 9.48 | 7.6 |
| Weighted Avg Shares Out | 51 | 51 | 51 | 50 |
| Weighted Avg Shares Out Dil | 52 | 51 | 51 | 51 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $5 | $1 | $1 |
| Interest Expense | $126 | $137 | $59 | $74 |
| Depreciation & Amortization | $362 | $314 | $304 | $266 |
| EBITDA | $581 | $1,032 | $986 | $820 |
| % Margin | 14.3% | 25% | 24.8% | 23.2% |